RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 5, 2003, Pages 526-532

  Bourreille, A ^b   Doubremelle, M ^b   Raingeard De La Bletiere D ^b   Segain, J P ^b   Toquet, C ^b   Buelow, R ^b   Galmiche, J P ^a  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

Crohn disease; Inflammation; Inflammatory bowel disease; RDP58; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; GAMMA INTERFERON; INTERLEUKIN 1BETA; TRINITROBENZENESULFONIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BIOPSY; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; CROHN DISEASE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MODELS, ANIMAL; PEPTIDES; PROSPECTIVE STUDIES; RATS; RATS, SPRAGUE-DAWLEY; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038288682     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310002922     Document Type: Article

References (42)

1. Riley R. Crohn's disease and ulcerative colitis: morbidity and mortality. Health Rep 1990;2:343-59.
2. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
3. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payer perspective. Am J Gastroenterol 2000;95:1955-60.
4. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
5. Plevy SE, Targan SR, Deem RL, Toyoda H. Increased mucosal TNF-α levels and numbers of TNF-α producing cells are unique to Crohn's disease mucosal inflammation. Gastroenterology 1995;106:A754.
6. Braegger CP, Nicholls S, Murch SH, Stephen S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
7. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
8. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
9. Bouma G, Oudkerk Pool M, Scharenberg JG, Kolkman JJ, von Blomberg BM, Scheper RJ, et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100.
10. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1996;8:872-7.
11. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. N Engl J Med 1997;337:1029-35.
12. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
13. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α. and activates immune effector functions. Cytokine 1995;7:251-9.
14. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T Lymphocytes in Crohn's disease. Gut 2002;50:206-11.
15. Hanauer SB, Rutgeerts P, D'Haens G, Targan S, Kam L, Present DH, et al. Delayed hypersensitivity to infliximab (Remicade®) re-infusion after a 2-4-year interval without treatment. Gastroenterology 1999;116:A731.
16. Woo J, Gao L, Cornejo MC, Buelow R. A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Transplantation 1995;60:1156-63.
17. Gao L, Woo J, Buelow R. Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice. J Heart Lung Transplant 1996;15:78-87.
18. Hanaway MJ, Geissler EK, Wang J, Fechner JH Jr, Buelow R, Knechtle SJ. Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. Transplantation 1996;61:1222-8.
19. Murphy B, Kim KS, Buelow R, Sayegh MH, Hancock WW. Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis → Fischer 344 model of chronic allograft rejection. Transplantation 1997;64:14-9.
20. Woo J, lyer S, Cornejo MC, Gao L, Cuturi C, Soulillou JP, et al. Immunosuppression by D-isomers of HLA class I heavy chain (amino acid 75 to 84)-derived peptides is independent of binding to HSC70. Transplantation 1997;64:1460-7.
21. Iyer S, Woo J, Cornejo MC, Gao L, McCoubrey W, Maines M, et al. Characterization and biological significance of immunosuppressive peptide D2702.75-84 (E → V) binding protein. Isolation of heme oxygenase-1. J Biol Chem 1998;273:2692-7.
22. Grassy G, Calas B, Yasri A, Lahana R, Woo J, Iyer S, et al. Computer-assisted rational design of immunosuppressive compounds. Nat Biotechnol 1998;16:748-52.
23. Cuturi MC, Christoph F, Woo J, Iyer S, Brouard S, Heslan JM, et al. RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: analysis of its mechanism of action. Mol Med 1999;5:820-32.
24. Magee CC, Azuma H, Knoflach A, Denton MD, Chandraker A, Iyer S, et al. In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol 1999;10:1997-2005.
25. Iyer S, Kontoyiannis D, Chewier D, Woo J, Mori N, Cornejo M, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000;275:17051-7.
26. Bull DM, Bookman MA. Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest 1977;59:966-74.
27. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
28. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFkB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
29. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96: 795-803.
30. Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 1998;43:783-90.
31. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammation bowel disease. Gastroenterology 1989;96:29-36.
32. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
33. Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475-80.
34. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
35. Neurath M, Fuss I, Strober W. TNBS-colitis. Intern Rev Immunol 2000;19:51-62.
36. Neurath M, Fuss I, Kelsall B, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
37. Neurath M, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-50.
38. Murthy S, Flanigan A, Buelow R. The efficacy of RDP58 in the dextran sulfate (DSS) model of chronic colitis. Gastroenterology 2002;122:A397.
39. Ganesan S, Iyer S, Travis S, Roberts J, Buelow R, Jazrawi R, et al. RDP58, a new oral inhibitor of TNF effectively treats primate models of colitis and is safe in man. Gastroenterology 2002;122:A6.
40. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996;2:87-90.
41. Otterbein LE, Bach FH, Alum J, Soares M, Tao Lu H, Wysk M, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000;6:422-8.
42. Wang WP, Guo X, Koo MW, Wong BC, Lam SK, Ye YN, et al. Protective role of heme-oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 2001;28:586-94.